SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (1996)5/2/2000 12:42:00 PM
From: Jim Oravetz  Read Replies (1) of 2028
 
Bio-Technology General Corp. (BTGC) said first quarter Oxandrin prescriptions rose 11% compared with last year, and first quarter Oxandrin end-user sales rose 17%.
The biotechnology company also signed a co-marketing agreement with Abbott Laboratories (ABT) for Oxandrin, an oral anabolic agent indicated to promote weight gain after involuntary weight loss following surgery, chronic infections or severe trauma.
Oxandrin is also indicated for patients who, without definite pathophysiologic reasons, fail to gain or maintain normal weight.
Under the terms of the agreement, Oxandrin will be marketed in the U.S. by both companies to their traditional customers served by their respective sales forces.

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News